# Hypothalamic-Pituitary Axis Physiology

## Introduction and Anatomical Framework

### Hypothalamic Anatomy

The hypothalamus is a compact yet remarkably complex structure situated at the base of the brain, where it forms the floor and lateral walls of the third ventricle. Weighing approximately four grams, it serves as the critical integration center for endocrine, autonomic, and behavioral functions, acting as the principal interface between the nervous system and the endocrine system. The hypothalamus contains numerous functionally distinct nuclei, among which the supraoptic nucleus (SON), paraventricular nucleus (PVN), arcuate nucleus, ventromedial nucleus, dorsomedial nucleus, and suprachiasmatic nucleus are of particular endocrine relevance.

A key anatomical landmark is the median eminence, a circumventricular organ that lacks a complete blood-brain barrier. This unique feature allows hypophysiotropic hormones synthesized in hypothalamic neurons to be released into the portal circulation, thereby accessing the anterior pituitary without the restriction imposed by the blood-brain barrier elsewhere in the central nervous system. The hypothalamus houses two functionally distinct neuronal populations with regard to pituitary regulation: magnocellular neurons, located predominantly in the PVN and SON, project their axons directly into the posterior pituitary where they release vasopressin and oxytocin, while parvocellular neurons release their regulatory hormones into the hypophyseal portal system for delivery to the anterior pituitary.

### Hypophyseal Portal System

The hypophyseal portal system represents one of the most elegant vascular arrangements in the human body and is essential for hypothalamic-pituitary communication. The superior hypophyseal arteries, branches of the internal carotid arteries, form the primary capillary plexus within the median eminence. Hypothalamic releasing and inhibiting hormones are secreted into this primary plexus and then carried downward through long portal veins that descend along the pituitary stalk to the secondary capillary plexus within the anterior pituitary gland. Short portal vessels provide additional blood supply to the lower stalk and proximal anterior lobe.

An important and often underappreciated feature of this system is the capacity for retrograde flow, which enables ultrashort-loop feedback from pituitary hormones back to the hypothalamus. The clinical significance of the portal system becomes apparent when the pituitary stalk is transected or compressed by a mass lesion. Disruption of portal flow leads to the loss of stimulatory signals, causing most anterior pituitary axes to decline. The notable exception is prolactin, which paradoxically rises because its primary regulation is tonic inhibition by dopamine delivered through the portal system. Loss of this dopaminergic input results in hyperprolactinemia, a phenomenon known as the "stalk effect."

### Pituitary Gland Anatomy

The pituitary gland resides within the sella turcica, a bony depression in the sphenoid bone at the skull base. It weighs between 0.5 and 0.9 grams under normal conditions but enlarges during pregnancy to approximately 1.2 grams, primarily due to estrogen-driven lactotroph hyperplasia. The gland comprises three distinct lobes with different embryological origins. The anterior lobe, or adenohypophysis, constitutes roughly 80% of the gland volume and is derived from Rathke pouch, an invagination of oral ectoderm. The posterior lobe, or neurohypophysis, originates from neural ectoderm and maintains a direct neural connection to the hypothalamus through axonal projections. The intermediate lobe is vestigial in human adults but retains the capacity to produce POMC-derived peptides including alpha-melanocyte-stimulating hormone (alpha-MSH).

The anatomical relationships of the pituitary gland are of critical surgical and clinical importance. Laterally, the cavernous sinuses contain cranial nerves III, IV, V1, V2, and VI, as well as the internal carotid artery. The optic chiasm lies approximately 5 to 10 millimeters above the diaphragma sellae, explaining why suprasellar extension of pituitary masses characteristically produces bitemporal visual field defects.

<image>A detailed anatomical cross-section diagram of the hypothalamic-pituitary axis showing the hypothalamus with labeled nuclei (supraoptic, paraventricular, arcuate), the median eminence, the superior hypophyseal arteries forming the primary capillary plexus, long portal veins descending through the pituitary stalk, and the secondary capillary plexus in the anterior pituitary. The posterior pituitary should show direct axonal projections from magnocellular neurons. Label the optic chiasm, diaphragma sellae, cavernous sinuses, and internal carotid arteries. Use a sagittal view with clean medical illustration style.</image>

## Hypothalamic Releasing and Inhibiting Hormones

### Stimulatory Hormones

The hypothalamus produces several releasing hormones that stimulate anterior pituitary hormone synthesis and secretion, each with distinct biochemical characteristics and regulatory patterns.

Gonadotropin-releasing hormone (GnRH) is a 10-amino acid peptide whose pulsatile secretion pattern is essential for normal reproductive axis function. The critical importance of pulsatility cannot be overstated: pulsatile GnRH delivery stimulates LH and FSH secretion, whereas continuous GnRH exposure paradoxically suppresses gonadotropin release through receptor downregulation. The pulse frequency itself varies across the menstrual cycle, occurring approximately every 60 to 90 minutes during the follicular phase and slowing to every 2 to 4 hours during the luteal phase, a distinction that has important implications for the differential regulation of LH versus FSH.

Growth hormone-releasing hormone (GHRH) is a 44-amino acid peptide produced by neurons in the arcuate nucleus. It stimulates both GH synthesis and secretion through the GHRH receptor, a Gs-coupled receptor that activates the cAMP-protein kinase A signaling pathway in somatotrophs.

Corticotropin-releasing hormone (CRH) is a 41-amino acid peptide produced primarily by parvocellular neurons in the PVN. CRH acts synergistically with arginine vasopressin (AVP) to stimulate ACTH release from corticotrophs. The CRH-ACTH-cortisol axis exhibits a robust diurnal rhythm, with CRH secretion peaking in the early morning hours.

Thyrotropin-releasing hormone (TRH) is the simplest of the hypothalamic releasing hormones, consisting of just three amino acids in the modified sequence pyroGlu-His-Pro. In addition to its primary role stimulating TSH release from thyrotrophs, TRH also stimulates prolactin secretion from lactotrophs, which explains the mild hyperprolactinemia sometimes observed in primary hypothyroidism.

### Inhibitory Hormones

Hypothalamic inhibitory hormones provide a crucial counterbalance to the stimulatory signals and are of considerable therapeutic importance.

Somatostatin (SST) exists in 14- and 28-amino acid forms and serves as a potent inhibitor of both GH and TSH secretion. It exerts its effects through a family of five somatostatin receptor subtypes (SSTR1 through SSTR5), of which SSTR2 and SSTR5 are the most therapeutically relevant. The somatostatin receptor ligands used in clinical practice, including octreotide, lanreotide, and pasireotide, exploit these receptor subtypes for the treatment of acromegaly, neuroendocrine tumors, and other conditions.

Dopamine serves as the primary prolactin-inhibiting factor, providing tonic inhibition of prolactin secretion through D2 receptors on lactotrophs. This tonic inhibitory control makes prolactin unique among anterior pituitary hormones. The loss of dopaminergic input, whether from stalk compression, stalk transection, or pharmacological D2 receptor blockade, results in hyperprolactinemia.

Gonadotropin-inhibitory hormone (GnIH), also known as RFRP-3, has been identified as an inhibitor of GnRH neurons, although its precise role in human reproductive physiology remains an active area of investigation.

### Ghrelin and Other Modulators

Beyond the classical releasing and inhibiting hormones, several additional modulators play important roles in hypothalamic-pituitary regulation. Ghrelin, a 28-amino acid peptide produced primarily by the gastric fundus, acts as a potent GH secretagogue through the growth hormone secretagogue receptor 1a (GHS-R1a). Its identification led to the development of the macimorelin test for GH deficiency.

Kisspeptin, encoded by the KISS1 gene, has emerged as a critical upstream regulator of GnRH pulsatility. Loss-of-function mutations in the kisspeptin receptor cause hypogonadotropic hypogonadism, demonstrating its essential role in reproductive axis activation. Kisspeptin-producing neurons in the arcuate nucleus co-express neurokinin B and dynorphin, forming the KNDy (kisspeptin/neurokinin B/dynorphin) neuron system that serves as the pulse generator for GnRH secretion. This discovery has fundamentally reshaped our understanding of reproductive neuroendocrinology.

## Anterior Pituitary Axes

### Somatotroph Axis (GH-IGF-1)

Somatotrophs constitute approximately 50% of anterior pituitary cells, making them the most abundant cell type in the adenohypophysis. Growth hormone secretion is characteristically pulsatile, with the major secretory burst occurring during slow-wave sleep. This pulsatile pattern is not merely an epiphenomenon but is functionally important, as it drives sex-specific patterns of gene expression in the liver.

GH exerts both direct and indirect effects on target tissues. Direct actions include lipolysis in adipose tissue and insulin-antagonistic effects on glucose metabolism. Indirect effects are mediated primarily through hepatic production of insulin-like growth factor 1 (IGF-1), which mediates most of the growth-promoting actions of GH on bone, cartilage, and other tissues.

The regulation of GH secretion involves a complex interplay of stimulatory and inhibitory signals. GH secretion is stimulated by sleep, exercise, hypoglycemia, amino acids (particularly arginine), ghrelin, sex steroids, and GHRH. Conversely, GH secretion is inhibited by hyperglycemia, free fatty acids, IGF-1, somatostatin, and obesity. Negative feedback operates at multiple levels: IGF-1 inhibits GH secretion at the pituitary and suppresses GHRH at the hypothalamus, while GH itself stimulates hypothalamic somatostatin release through an ultrashort feedback loop. The differentiation of somatotrophs requires the transcription factor Pit-1, which is also necessary for lactotroph and thyrotroph development.

### Lactotroph Axis (Prolactin)

Lactotrophs comprise 15 to 25% of anterior pituitary cells and are unique in being the only anterior pituitary cell type under primary tonic inhibitory control. Prolactin secretion follows a pulsatile pattern with sleep-entrained peaks and increases substantially during pregnancy, driven by estrogen-mediated lactotroph hyperplasia.

Prolactin release is stimulated by TRH, vasoactive intestinal peptide (VIP), estrogen, serotonin, and the suckling reflex. Its primary inhibition comes from dopamine, with GnRH-associated peptide (GAP) providing additional inhibitory input. An important clinical consequence of prolactin's physiology is its inhibitory effect on GnRH pulsatility, which explains the hypogonadism observed in states of hyperprolactinemia.

The concept of the "stalk effect" is of major clinical importance. Any mass lesion compressing the pituitary stalk can interrupt dopamine delivery to lactotrophs, causing prolactin to rise, typically to levels of 25 to 150 ng/mL. This range must be distinguished from prolactinoma-associated hyperprolactinemia, where levels exceeding 200 ng/mL are strongly suggestive of a prolactin-secreting tumor.

### Corticotroph Axis (HPA)

Corticotrophs represent 15 to 20% of anterior pituitary cells and express the proopiomelanocortin (POMC) gene, which is processed to yield ACTH (amino acids 1-39), beta-lipotropin, and beta-endorphin. Both CRH and AVP stimulate ACTH secretion, acting synergistically through their respective receptors. AVP acts through the V1b receptor (also termed V3) on corticotrophs.

The HPA axis exhibits a robust circadian rhythm, with ACTH levels peaking between 06:00 and 09:00 and reaching their nadir between 23:00 and 01:00. Cortisol secretion follows ACTH with a 30 to 60 minute delay. Superimposed on this circadian pattern is an ultradian pulsatility, with approximately 7 to 15 secretory pulses occurring per day. These ultradian pulses are increasingly recognized as important for proper glucocorticoid receptor cycling and transcriptional regulation at target tissues.

Negative feedback is mediated by cortisol acting through the glucocorticoid receptor at both the hypothalamus, where it suppresses CRH synthesis, and the pituitary, where it inhibits ACTH secretion. However, stress, whether physical, psychological, or inflammatory, can override negative feedback, driving cortisol levels to 3 to 5 times baseline values. This stress response is a vital survival mechanism but also underlies the pathophysiology of critical illness-related cortisol dynamics.

### Thyrotroph Axis (HPT)

Thyrotrophs are the least abundant anterior pituitary cell type, comprising approximately 5% of the cell population. They produce TSH, a glycoprotein hormone consisting of an alpha subunit shared with LH, FSH, and hCG, and a unique beta subunit that confers biological specificity.

TSH secretion exhibits diurnal variation with a nocturnal surge peaking around midnight. One of the most clinically important features of the thyrotroph axis is the log-linear inverse relationship between free T4 and TSH. This means that a 2-fold change in free T4 concentration produces an approximately 100-fold change in TSH, making TSH an exquisitely sensitive marker of primary thyroid dysfunction. This amplified sensitivity is the reason TSH is the preferred first-line test for thyroid function assessment in ambulatory patients.

Within thyrotrophs, type 2 deiodinase converts circulating T4 to the biologically active T3 intracellularly. T3 is the primary mediator of negative feedback, suppressing both TRH gene expression in the hypothalamus and TSH synthesis and secretion at the pituitary level.

### Gonadotroph Axis (HPG)

Gonadotrophs account for approximately 10% of anterior pituitary cells and are unique in producing two distinct hormones, LH and FSH, from the same cell type. Both are glycoprotein hormones sharing the same alpha subunit but possessing unique beta subunits.

A fundamental concept in reproductive endocrinology is that GnRH pulse frequency differentially regulates LH and FSH production: fast-frequency pulses preferentially stimulate LH beta subunit transcription, while slow-frequency pulses favor FSH beta subunit expression. This frequency-dependent regulation is the mechanistic basis for the changing LH-to-FSH ratios observed across the menstrual cycle.

Feedback regulation differs between males and females. In males, testosterone provides negative feedback on LH secretion at both the hypothalamic and pituitary levels, while inhibin B from Sertoli cells selectively inhibits FSH at the pituitary. In females, estradiol exerts dual feedback depending on concentration and duration of exposure: at low concentrations, it provides negative feedback, while sustained high concentrations trigger the positive feedback mechanism that generates the preovulatory LH surge. Inhibin A and B contribute to FSH regulation, while activin stimulates FSH secretion and follistatin neutralizes activin by direct binding.

<image>A comprehensive flowchart showing all five anterior pituitary axes arranged side by side. For each axis, show the hypothalamic hormone at top, the pituitary cell type and hormone in the middle, and the target gland hormone at bottom. Use green arrows for stimulation and red lines with flat ends for inhibition/negative feedback. Include: GHRH/Somatostatin to Somatotroph to GH to IGF-1; Dopamine(inhibitory)/TRH to Lactotroph to Prolactin; CRH/AVP to Corticotroph to ACTH to Cortisol; TRH to Thyrotroph to TSH to T4/T3; GnRH to Gonadotroph to LH/FSH to Sex Steroids. Show feedback loops clearly with dashed red arrows.</image>

## Posterior Pituitary Hormones

### Vasopressin (AVP/ADH)

Arginine vasopressin (AVP), also known as antidiuretic hormone (ADH), is synthesized in the magnocellular neurons of the supraoptic and paraventricular nuclei as part of a preprohormone complex. This precursor is co-translationally processed and packaged with neurophysin II and copeptin into neurosecretory granules, which are then transported via axonal projections through the pituitary stalk to the posterior pituitary, where they are stored and released into the systemic circulation.

The primary physiological stimulus for AVP release is plasma osmolality. Osmoreceptors located in the organum vasculosum of the lamina terminalis (OVLT) and the subfornical organ (SFO), both circumventricular organs, detect changes in plasma osmolality with remarkable sensitivity. The osmotic threshold for AVP release is approximately 280 to 285 mOsm/kg, above which AVP secretion increases in a linear fashion proportional to osmolality. Non-osmotic stimuli can also drive AVP release, including hypovolemia (requiring greater than 7 to 10% volume depletion), hypotension, nausea, pain, stress, and angiotensin II.

AVP acts through three receptor subtypes distributed across different tissues: V1a receptors on vascular smooth muscle mediate vasoconstriction, V1b (also termed V3) receptors on anterior pituitary corticotrophs contribute to ACTH release, and V2 receptors on renal collecting duct principal cells promote the insertion of aquaporin-2 water channels, enabling water reabsorption. Copeptin, the C-terminal fragment of the AVP precursor, is a stable surrogate marker for AVP and is increasingly used in clinical assays for the workup of diabetes insipidus, given its superior stability compared to AVP itself.

### Oxytocin

Oxytocin is synthesized primarily in magnocellular neurons of the paraventricular nucleus and is packaged with neurophysin I for transport to the posterior pituitary. Its classical physiological roles include stimulation of uterine smooth muscle contraction during labor and the milk ejection reflex during lactation. Oxytocin release is triggered by suckling and by cervical and vaginal distension, the latter known as the Ferguson reflex. Emerging research has expanded the recognized roles of oxytocin to include modulation of social bonding, anxiety regulation, and potential metabolic effects, although many of these functions in humans remain under active investigation.

## Feedback Mechanisms

### Levels of Feedback

The hypothalamic-pituitary-target gland axes operate through a hierarchical feedback system that maintains hormonal homeostasis with remarkable precision. Three levels of feedback have been characterized.

Long-loop feedback is the most clinically recognized mechanism, in which target gland hormones, including cortisol, thyroid hormones, sex steroids, and IGF-1, feed back to both the hypothalamus and the pituitary to suppress the secretion of their respective releasing hormones and trophic hormones. Short-loop feedback involves pituitary hormones feeding back to the hypothalamus to modulate releasing hormone secretion. For example, GH inhibits GHRH secretion, and ACTH modulates CRH release. Ultrashort-loop feedback refers to the capacity of hypothalamic hormones to regulate their own secretion, as exemplified by GnRH modulating its own neuronal activity.

### Clinical Implications of Feedback Disruption

Understanding feedback mechanisms is essential for clinical practice, as exogenous hormones and various medications can profoundly disrupt these feedback loops. Exogenous glucocorticoid administration suppresses CRH and ACTH secretion, leading to progressive adrenal cortical atrophy. Abrupt withdrawal of glucocorticoids in this setting carries the risk of adrenal crisis, a potentially fatal condition. Anabolic steroid use suppresses GnRH and gonadotropin secretion, resulting in hypogonadotropic hypogonadism and infertility that may persist for months after discontinuation. Chronic opioid use suppresses GnRH, CRH, and potentially GHRH, causing a syndrome of opioid-induced endocrinopathy that is increasingly recognized in clinical practice. Post-oral-contraceptive amenorrhea reflects transient suppression of the HPG axis, which typically recovers within several months of discontinuation.

<image>A circular feedback diagram focusing on the HPA axis as an exemplar of multilevel feedback. Show the hypothalamus (CRH and AVP neurons) at top, anterior pituitary (corticotrophs producing ACTH) in the middle, and adrenal cortex (zona fasciculata producing cortisol) at the bottom. Illustrate the long-loop negative feedback of cortisol on both hypothalamus and pituitary with red inhibitory arrows, short-loop feedback of ACTH on hypothalamic CRH with an orange arrow, and the stimulatory effects of stress (physical, psychological, inflammatory cytokines IL-1, IL-6, TNF-alpha) overriding the negative feedback with bold green arrows from external inputs. Include a clock icon indicating circadian rhythm input from the suprachiasmatic nucleus.</image>

## Pituitary Development and Transcription Factors

### Embryology

The pituitary gland has a dual embryological origin that reflects its functional division into anterior and posterior components. The anterior lobe develops from Rathke pouch, an invagination of oral ectoderm that appears around the fourth week of embryonic development. This pouch ascends to meet the infundibulum, a downgrowth of neural ectoderm from the diencephalon, which gives rise to the posterior pituitary and the pituitary stalk. Rathke cleft cysts represent remnants of Rathke pouch and can persist into adulthood, where they may be found incidentally on imaging or, when large, cause compressive symptoms mimicking pituitary adenomas.

### Key Transcription Factors

The differentiation of anterior pituitary progenitor cells into the five mature hormone-producing cell types is directed by a cascade of transcription factors whose clinical significance extends far beyond embryology, as mutations in these factors cause congenital hypopituitarism.

| Transcription Factor | Gene | Cell Lineage | Hormone Deficiencies | Key Clinical Features |
|---|---|---|---|---|
| Pit-1 | POU1F1 | Somatotroph, Lactotroph, Thyrotroph | GH, Prolactin, TSH | Combined pituitary hormone deficiency |
| PROP1 | PROP1 | Pit-1-dependent + Gonadotroph | GH, Prolactin, TSH, LH, FSH (± late ACTH) | Most common genetic cause of CPHD |
| TPIT | TBX19 | Corticotroph | Isolated ACTH | Neonatal hypoglycemia, adrenal insufficiency |
| SF-1 | NR5A1 | Gonadotroph | LH, FSH | Hypogonadotropic hypogonadism |
| HESX1 | HESX1 | Early pituitary development | Variable | Septo-optic dysplasia |
| LHX3 | LHX3 | Multiple lineages | GH, Prolactin, TSH, LH, FSH | Structural pituitary abnormalities |
| LHX4 | LHX4 | Multiple lineages | Variable combined | Structural pituitary abnormalities |

Pit-1 (POU1F1) is required for the differentiation and maintenance of somatotrophs, lactotrophs, and thyrotrophs. Mutations in Pit-1 result in combined pituitary hormone deficiency involving GH, prolactin, and TSH. PROP1 is a paired-like homeodomain transcription factor that acts upstream of Pit-1 and is necessary for the development of Pit-1-dependent lineages as well as gonadotrophs. PROP1 mutations represent the most common genetic cause of combined pituitary hormone deficiency, producing deficiencies of GH, prolactin, TSH, LH, and FSH, with ACTH deficiency occasionally developing later in life.

TPIT (TBX19) is specifically required for corticotroph differentiation, and its mutations cause isolated ACTH deficiency, which can present with life-threatening neonatal hypoglycemia and adrenal insufficiency. SF-1 (NR5A1) drives gonadotroph differentiation. HESX1 is involved in early pituitary development, and its mutations are associated with septo-optic dysplasia, a syndrome that includes optic nerve hypoplasia, midline brain defects, and pituitary hormone deficiencies. LHX3 and LHX4 are LIM-homeodomain transcription factors whose mutations cause combined deficiencies often accompanied by structural abnormalities of the pituitary and surrounding structures.

## Pulsatility and Rhythmicity

### Importance of Pulsatile Secretion

The pulsatile nature of hypothalamic and pituitary hormone secretion is not merely a curiosity but a fundamental requirement for normal physiological function. The GnRH axis provides the most dramatic illustration: continuous GnRH administration leads to downregulation of GnRH receptors on gonadotrophs, resulting in suppression rather than stimulation of LH and FSH secretion. This paradoxical effect is the pharmacological basis for GnRH agonist therapy in prostate cancer, endometriosis, central precocious puberty, and other conditions where gonadal suppression is desired.

GH secretion follows a pulsatile pattern with 6 to 12 discrete pulses per day. This pulsatile delivery is essential for the sex-specific patterns of hepatic gene expression that GH regulates, a distinction that has implications for understanding sexual dimorphism in drug metabolism and other liver functions. ACTH and cortisol exhibit ultradian pulsatility that is increasingly recognized as important for proper glucocorticoid receptor cycling and downstream transcriptional regulation in target tissues.

### Circadian Regulation

The suprachiasmatic nucleus (SCN) of the hypothalamus serves as the master circadian pacemaker, entrained to the environmental light-dark cycle via the retinohypothalamic tract. At the molecular level, the circadian clock operates through transcription-translation feedback loops involving the clock genes CLOCK, BMAL1, PER, and CRY, which generate an approximately 24-hour oscillation in gene expression.

The HPA axis exhibits one of the most robust circadian rhythms in human physiology, with cortisol levels varying by as much as 10-fold between the morning peak and the midnight nadir. This rhythm is disrupted in shift workers, jet lag, and, pathologically, in Cushing syndrome, where loss of the normal cortisol nadir is an early and diagnostically useful finding. The GH axis shows its major secretory burst during slow-wave sleep, and sleep deprivation predictably reduces GH secretion. The TSH axis displays a nocturnal surge that is suppressed by sleep itself; paradoxically, acute sleep deprivation transiently increases TSH levels.

## Clinical Assessment of the Hypothalamic-Pituitary Axis

### Basal Hormone Testing

The cornerstone principle of pituitary hormone assessment is that pituitary hormones must always be interpreted in the context of their corresponding target gland hormones. A pituitary hormone level that appears "normal" in isolation may be entirely inappropriate for the clinical setting. For example, a low free T4 with a low or normal TSH does not indicate normal thyroid function but rather points to central hypothyroidism, where the expected elevation in TSH fails to occur.

Morning cortisol measurement, drawn at approximately 08:00, provides a useful screening test for adrenal reserve. A value below 3 mcg/dL strongly suggests cortisol deficiency, while a value above 15 to 18 mcg/dL generally excludes it. Values in the intermediate range require dynamic testing for definitive assessment. IGF-1 serves as an integrator of GH secretion over time, but its interpretation requires age- and sex-adjusted reference ranges, as IGF-1 levels decline physiologically with aging. Prolactin levels must be interpreted carefully: mild elevations of 25 to 100 ng/mL have a broad differential diagnosis including medications, stalk effect, and hypothyroidism, while levels exceeding 200 ng/mL in the presence of a macroadenoma are virtually diagnostic of a prolactinoma.

### Dynamic Testing

| Test | Axis Assessed | Stimulus | Normal Response | Key Contraindications |
|---|---|---|---|---|
| Insulin Tolerance Test (ITT) | GH + ACTH | Hypoglycemia (glucose <40 mg/dL) | GH >5 ng/mL; Cortisol >18 mcg/dL | Seizure disorders, CAD, elderly |
| Cosyntropin Stim (250 mcg) | ACTH/Adrenal | Synthetic ACTH IV | Cortisol >18 mcg/dL at 30-60 min | May miss early secondary AI |
| Low-dose Cosyntropin (1 mcg) | ACTH/Adrenal | Synthetic ACTH IV | Cortisol >18 mcg/dL | Less standardized |
| Glucagon Stim Test | GH + ACTH | Glucagon 1 mg IM | GH >3 ng/mL; Cortisol >18 mcg/dL | Alternative when ITT contraindicated |
| Macimorelin Test | GH | Oral GH secretagogue | GH >2.8 ng/mL | CYP3A4 interactions, QTc drugs |
| CRH Stim Test | ACTH (Cushing DDx) | CRH IV | Differentiates pituitary vs ectopic ACTH | Used in Cushing workup |

When basal testing yields indeterminate results, dynamic stimulation tests are employed to assess pituitary reserve. The insulin tolerance test (ITT) is considered the gold standard for simultaneously assessing both GH and ACTH reserve. It requires the induction of symptomatic hypoglycemia with a blood glucose below 40 mg/dL, which provides a potent stress stimulus to the hypothalamic-pituitary axis. However, the ITT is contraindicated in patients with seizure disorders, coronary artery disease, and the elderly, and requires physician supervision throughout.

The cosyntropin stimulation test using 250 mcg of synthetic ACTH administered intravenously evaluates adrenal cortisol reserve. A peak cortisol response exceeding 18 mcg/dL (500 nmol/L) at 30 or 60 minutes is considered a normal response. An important limitation is that this test may miss early or mild secondary adrenal insufficiency, because adrenal atrophy from ACTH deprivation requires several weeks to develop. The low-dose cosyntropin test using 1 mcg may be more sensitive for detecting partial secondary adrenal insufficiency but is less standardized.

For GH axis assessment, the glucagon stimulation test serves as the primary alternative to the ITT when the latter is contraindicated. The macimorelin test, an oral GH secretagogue that has received FDA approval, offers a convenient and well-tolerated option for diagnosing adult GH deficiency. The CRH stimulation test is used primarily in the differential diagnosis of Cushing syndrome, distinguishing pituitary from ectopic ACTH sources. The GnRH stimulation test has limited utility in adults but can be valuable in adolescents for distinguishing constitutional delay of puberty from hypogonadotropic hypogonadism.

<image>A clinical algorithm flowchart for evaluating suspected hypopituitarism. Start with clinical suspicion (fatigue, hypogonadism, growth failure). Branch into basal testing: morning cortisol, free T4, TSH, IGF-1, LH, FSH, testosterone/estradiol, prolactin. For indeterminate results, branch into dynamic tests: ITT or cosyntropin stim test for ACTH axis, GH stim test (glucagon or macimorelin) for GH axis. Show decision points with specific cut-off values. Include a box listing when to obtain pituitary MRI. Use clean flowchart style with rectangular process boxes, diamond decision nodes, and color-coded pathways for each axis.</image>

## Key Clinical Pearls

- The "stalk effect" causes hyperprolactinemia (typically 25-150 ng/mL) from any mass compressing the stalk, due to loss of dopaminergic inhibition; prolactin >200 ng/mL with a macroadenoma is a prolactinoma until proven otherwise
- In central hypothyroidism, TSH can be low, normal, or even mildly elevated (biologically inactive isoforms); free T4, not TSH, is the monitoring target
- Pulsatility of GnRH is critical: pulsatile GnRH restores fertility while continuous GnRH (or agonists) suppresses the gonadal axis -- this principle underlies major therapeutic applications
- The log-linear TSH-free T4 relationship means small changes in thyroid function cause amplified TSH changes, making TSH the most sensitive marker of primary thyroid dysfunction
- Empty sella on imaging does not necessarily imply hypopituitarism; functional testing is required
- After pituitary surgery or radiation, hormone deficiencies may evolve over months to years; GH and gonadotropins are typically lost first, ACTH and TSH later

## References

1. Melmed S, et al. "Pituitary Physiology and Diagnostic Evaluation." In: Williams Textbook of Endocrinology, 14th edition, Elsevier, 2020.
2. Arafah BM, Nasrallah MP. "Pituitary tumors: pathophysiology, clinical manifestations and management." Endocr Relat Cancer. 2001;8(4):287-305.
3. Korbonits M, et al. "The Growth Hormone Secretagogue Receptor." Growth Horm IGF Res. 2004;14 Suppl A:S1-S8.
4. Steyn FJ, et al. "Regulation of the Hypothalamo-Pituitary-Adrenal Axis by Pulsatile Cortisol." J Endocrinol. 2016;231(3):R1-R15.
5. Fleseriu M, et al. "Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline." J Clin Endocrinol Metab. 2016;101(11):3888-3921.